Boston Scientific/$BSX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Ticker
$BSX
Sector
Primary listing
NYSE
Employees
53,000
Headquarters
Website
BSX Metrics
BasicAdvanced
$148B
59.44
$1.68
0.66
-
Price and volume
Market cap
$148B
Beta
0.66
52-week high
$109.50
52-week low
$80.64
Average daily volume
6.6M
Financial strength
Current ratio
1.372
Quick ratio
0.645
Long term debt to equity
50.973
Total debt to equity
53.092
Interest coverage (TTM)
10.60%
Profitability
EBITDA (TTM)
4,705
Gross margin (TTM)
68.69%
Net profit margin (TTM)
13.55%
Operating margin (TTM)
18.33%
Effective tax rate (TTM)
16.73%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
5.39%
Return on equity (TTM)
11.55%
Valuation
Price to earnings (TTM)
59.442
Price to revenue (TTM)
7.971
Price to book
6.65
Price to tangible book (TTM)
-50.67
Price to free cash flow (TTM)
42.057
Free cash flow yield (TTM)
2.38%
Free cash flow per share (TTM)
2.375
Growth
Revenue change (TTM)
21.44%
Earnings per share change (TTM)
36.90%
3-year revenue growth (CAGR)
14.47%
10-year revenue growth (CAGR)
9.78%
3-year earnings per share growth (CAGR)
42.56%
10-year earnings per share growth (CAGR)
30.29%
What the Analysts think about BSX
Analyst ratings (Buy, Hold, Sell) for Boston Scientific stock.
Bulls say / Bears say
Boston Scientific raised its 2025 adjusted EPS guidance to $2.95–$2.99 after better-than-expected second-quarter results driven by strong demand for heart devices (Reuters).
The cardiovascular division delivered $3.34 billion in Q2 revenue, beating estimates, with key growth from Farapulse and Watchman heart rhythm management systems (Reuters).
Analysts noted that hospital usage trends remain strong and consider Boston Scientific well-positioned to benefit from the expanding pulsed field ablation (PFA) market (Reuters).
The NECTAR-HF trial of Boston Scientific’s vagus nerve stimulation device did not show benefit in heart failure patients, raising concerns about its neuromodulation pipeline (Reuters).
Management pointed to broader healthcare spending pressures as a headwind, which could prompt hospitals to limit elective procedures and impact device sales (Reuters).
Competition from Johnson & Johnson’s Varipulse and Medtronic’s PulseSelect in the pulsed field ablation (PFA) segment could erode Boston Scientific’s market share and pricing power over time (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BSX Financial Performance
Revenues and expenses
BSX Earnings Performance
Company profitability
BSX News
AllArticlesVideos
3 Biotech Catalysts Present Major Opportunity
MarketBeat3 weeks ago
Uber Leads 5 Stocks Near Buy Points As Market Rebounds
Investors Business Daily3 weeks ago
Former FDA Director and Boston Scientific Leaders Join Keyron Ahead of Human Trials of First Device with Metabolic Surgery-Like Results Without Incisions
Business Wire1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Boston Scientific stock?
Boston Scientific (BSX) has a market cap of $148B as of September 16, 2025.
What is the P/E ratio for Boston Scientific stock?
The price to earnings (P/E) ratio for Boston Scientific (BSX) stock is 59.44 as of September 16, 2025.
Does Boston Scientific stock pay dividends?
No, Boston Scientific (BSX) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Boston Scientific dividend payment date?
Boston Scientific (BSX) stock does not pay dividends to its shareholders.
What is the beta indicator for Boston Scientific?
Boston Scientific (BSX) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.